Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations.

Cheng HH, Callis S, Yu EY, Delacroix SE, Sokolova AO, Tangen CM, Lerner SP, Dorff TB, Lin DW

Open source

DOI
10.1016/j.euf.2025.11.011
Published
2026 Jan
Container
European urology focus
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.euf.2025.11.011,
  title = {Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations.},
  author = {Cheng HH and Callis S and Yu EY and Delacroix SE and Sokolova AO and Tangen CM and Lerner SP and Dorff TB and Lin DW},
  year = {2026},
  journal = {European urology focus},
  doi = {10.1016/j.euf.2025.11.011},
  url = {https://doi.org/10.1016/j.euf.2025.11.011}
}

RIS

TY  - JOUR
TI  - Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations.
AU  - Cheng HH
AU  - Callis S
AU  - Yu EY
AU  - Delacroix SE
AU  - Sokolova AO
AU  - Tangen CM
AU  - Lerner SP
AU  - Dorff TB
AU  - Lin DW
PY  - 2026
JO  - European urology focus
DO  - 10.1016/j.euf.2025.11.011
UR  - https://doi.org/10.1016/j.euf.2025.11.011
ER  - 

APA

HH, C., S, C., EY, Y., SE, D., AO, S., CM, T., SP, L., TB, D., & DW, L. (2026). Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 Mutations.. European urology focus. https://doi.org/10.1016/j.euf.2025.11.011

Source records